GLCM is pleased to announce that the progression of the enhanced graphene sensor used in the immediate verification kit, which is an in vitro diagnostic device that produces a signal when exposed to COVID-19 viral antigens, has ended. With the final touch of positive identity of viral antigens, GLCM initiated the progression of a functional prototype of immediate reaction verification. GLCM hopes to gain benefits from regulatory needs and accelerated clinical trials, as announced through several regulators, adding Health Canada and the U.S. FDA.
The COVID-19 verification at the GLCM service point will offer exclusive merit over other verifications, as it detects the presence of the COVID-19 virus. To date, other advertised competitive controls are basically nucleic acid controls and serological controls. Serological controls are designed to identify the IgM and IgG antibodies they provide after infection. Nucleic acid controls identify an active infection, however, they still require the use of nasopharyngeal swab and the effects will have to be interpreted through a qualified medical apparatus that is a slow process. Serological and nucleic controls produce false positive and false negative effects, while GLCM control was developed to imply a positive result only when the COVID-19 virus is provided, allowing for direct and transparent interpretation through the user.